ZA200210277B - Melanocortin receptor ligands. - Google Patents
Melanocortin receptor ligands. Download PDFInfo
- Publication number
- ZA200210277B ZA200210277B ZA200210277A ZA200210277A ZA200210277B ZA 200210277 B ZA200210277 B ZA 200210277B ZA 200210277 A ZA200210277 A ZA 200210277A ZA 200210277 A ZA200210277 A ZA 200210277A ZA 200210277 B ZA200210277 B ZA 200210277B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- benzyl
- independently
- hydrogen
- ethyl
- Prior art date
Links
- 102000004378 Melanocortin Receptors Human genes 0.000 title claims description 6
- 108090000950 Melanocortin Receptors Proteins 0.000 title claims description 6
- 239000003446 ligand Substances 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 107
- 150000001875 compounds Chemical class 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- -1 hydroxy, nitro, amino, cyano, phenyl Chemical group 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 230000036528 appetite Effects 0.000 claims description 8
- 235000019789 appetite Nutrition 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 6
- 235000012631 food intake Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000005907 alkyl ester group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 2
- 208000007976 Ketosis Diseases 0.000 claims description 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000674 adrenergic antagonist Substances 0.000 claims description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000003529 anticholesteremic agent Substances 0.000 claims description 2
- 229940127226 anticholesterol agent Drugs 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 230000004634 feeding behavior Effects 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000004140 ketosis Effects 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000037323 metabolic rate Effects 0.000 claims description 2
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims description 2
- 150000004713 phosphodiesters Chemical class 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003352 sequestering agent Substances 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- OOAQRHNPIWYHIL-GCJKJVERSA-N (8aS)-7-[(2R)-2-amino-3-(4-chlorophenyl)propanoyl]-8a-(pyridin-3-ylmethyl)-2-(2,2,2-trifluoroethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1,3-dione Chemical compound C([C@@H](N)C(=O)N1C[C@@]2(CC=3C=NC=CC=3)C(=O)N(CC(F)(F)F)C(=O)N2CC1)C1=CC=C(Cl)C=C1 OOAQRHNPIWYHIL-GCJKJVERSA-N 0.000 claims 1
- MIVKGLRFZYNBJK-LCQOSCCDSA-N 7-[(2R)-2-amino-3-(4-chlorophenyl)propanoyl]-8a-[(4-fluorophenyl)methyl]-1,5,6,8-tetrahydro-[1,3]oxazolo[3,4-a]pyrazin-3-one Chemical compound C([C@@H](N)C(=O)N1CC2(CC=3C=CC(F)=CC=3)COC(=O)N2CC1)C1=CC=C(Cl)C=C1 MIVKGLRFZYNBJK-LCQOSCCDSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101150004219 MCR1 gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000008064 Corticotropin Receptors Human genes 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical group CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21461600P | 2000-06-28 | 2000-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200210277B true ZA200210277B (en) | 2003-12-19 |
Family
ID=22799775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200210277A ZA200210277B (en) | 2000-06-28 | 2002-12-19 | Melanocortin receptor ligands. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20020072604A1 (pt) |
| EP (1) | EP1294719A1 (pt) |
| JP (1) | JP2004501917A (pt) |
| KR (1) | KR20030017571A (pt) |
| CN (1) | CN1440406A (pt) |
| AP (1) | AP2001002196A0 (pt) |
| AR (1) | AR030301A1 (pt) |
| AU (1) | AU2001260548A1 (pt) |
| BG (1) | BG107268A (pt) |
| BR (1) | BR0111567A (pt) |
| CA (1) | CA2412563A1 (pt) |
| EA (1) | EA200201119A1 (pt) |
| EC (1) | ECSP024404A (pt) |
| IL (1) | IL152781A0 (pt) |
| IS (1) | IS6617A (pt) |
| MA (1) | MA26920A1 (pt) |
| MX (1) | MXPA03000063A (pt) |
| NO (1) | NO20026280L (pt) |
| OA (1) | OA12296A (pt) |
| PA (1) | PA8521501A1 (pt) |
| PE (1) | PE20020208A1 (pt) |
| PL (1) | PL360855A1 (pt) |
| TN (1) | TNSN01097A1 (pt) |
| UY (1) | UY26804A1 (pt) |
| WO (1) | WO2002000654A1 (pt) |
| ZA (1) | ZA200210277B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001264977B2 (en) * | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
| CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| US6911447B2 (en) * | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| WO2003013571A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
| TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| EP1595867A4 (en) | 2003-02-10 | 2008-05-21 | Banyu Pharma Co Ltd | PIPERIDINE DERIVATIVES AS AN ACTIVE ANTAGONIST AT THE RECIPE OF MELANIN CONCENTRATING HORMONE |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7795267B2 (en) | 2003-08-29 | 2010-09-14 | Takeda Pharmaceutical Company Limited | Bicyclic piperazine compound having TGR23 antagonistic activity |
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| DE602005026380D1 (de) * | 2004-04-08 | 2011-03-31 | Astellas Pharma Inc | Verbindung ws727713 |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| ES2877349T3 (es) * | 2005-07-08 | 2021-11-16 | Ipsen Pharma | Ligandos de los receptores de la melanocortina |
| CA2617546C (en) | 2005-08-03 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
| EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| EP2039695A4 (en) | 2006-07-11 | 2010-09-15 | Takeda Pharmaceutical | BICYCLIC HETEROCYLIC COMPOUND AND ITS USE |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| JP5220746B2 (ja) | 2006-08-25 | 2013-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 制御放出システム及びその製造方法 |
| RU2450017C2 (ru) | 2007-05-25 | 2012-05-10 | Ипсен Фарма С.А.С. | Лиганды меланокортиновых рецепторов, модифицированные гидантоином |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| US8288397B2 (en) | 2007-12-17 | 2012-10-16 | Janssen Pharmaceutica Nv | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076649A4 (en) * | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| EP1085869A4 (en) * | 1998-06-11 | 2001-10-04 | Merck & Co Inc | SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS |
| WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
-
2001
- 2001-05-31 KR KR1020027017822A patent/KR20030017571A/ko not_active Application Discontinuation
- 2001-05-31 EA EA200201119A patent/EA200201119A1/ru unknown
- 2001-05-31 WO PCT/IB2001/000995 patent/WO2002000654A1/en not_active Application Discontinuation
- 2001-05-31 OA OA1200200389A patent/OA12296A/en unknown
- 2001-05-31 AP APAP/P/2001/002196A patent/AP2001002196A0/en unknown
- 2001-05-31 MX MXPA03000063A patent/MXPA03000063A/es unknown
- 2001-05-31 PL PL36085501A patent/PL360855A1/xx not_active Application Discontinuation
- 2001-05-31 JP JP2002505778A patent/JP2004501917A/ja not_active Withdrawn
- 2001-05-31 IL IL15278101A patent/IL152781A0/xx unknown
- 2001-05-31 CN CN01812163A patent/CN1440406A/zh active Pending
- 2001-05-31 CA CA002412563A patent/CA2412563A1/en not_active Abandoned
- 2001-05-31 BR BR0111567-7A patent/BR0111567A/pt not_active IP Right Cessation
- 2001-05-31 AU AU2001260548A patent/AU2001260548A1/en not_active Abandoned
- 2001-05-31 EP EP01934254A patent/EP1294719A1/en not_active Withdrawn
- 2001-06-25 US US09/891,026 patent/US20020072604A1/en not_active Abandoned
- 2001-06-26 PE PE2001000626A patent/PE20020208A1/es not_active Application Discontinuation
- 2001-06-26 AR ARP010103037A patent/AR030301A1/es unknown
- 2001-06-27 TN TNTNSN01097A patent/TNSN01097A1/fr unknown
- 2001-06-27 UY UY26804A patent/UY26804A1/es not_active Application Discontinuation
- 2001-06-28 PA PA20018521501A patent/PA8521501A1/es unknown
-
2002
- 2002-11-12 BG BG107268A patent/BG107268A/xx unknown
- 2002-11-14 IS IS6617A patent/IS6617A/is unknown
- 2002-12-19 ZA ZA200210277A patent/ZA200210277B/en unknown
- 2002-12-24 MA MA26976A patent/MA26920A1/fr unknown
- 2002-12-26 EC EC2002004404A patent/ECSP024404A/es unknown
- 2002-12-30 NO NO20026280A patent/NO20026280L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL360855A1 (en) | 2004-09-20 |
| WO2002000654A1 (en) | 2002-01-03 |
| EA200201119A1 (ru) | 2003-06-26 |
| OA12296A (en) | 2006-05-12 |
| NO20026280D0 (no) | 2002-12-30 |
| EP1294719A1 (en) | 2003-03-26 |
| MXPA03000063A (es) | 2003-09-25 |
| CA2412563A1 (en) | 2002-01-03 |
| KR20030017571A (ko) | 2003-03-03 |
| AU2001260548A1 (en) | 2002-01-08 |
| AP2001002196A0 (en) | 2002-12-21 |
| NO20026280L (no) | 2002-12-30 |
| BG107268A (en) | 2003-06-30 |
| BR0111567A (pt) | 2003-05-06 |
| PA8521501A1 (es) | 2002-10-24 |
| UY26804A1 (es) | 2002-01-31 |
| IL152781A0 (en) | 2003-06-24 |
| CN1440406A (zh) | 2003-09-03 |
| MA26920A1 (fr) | 2004-12-20 |
| AR030301A1 (es) | 2003-08-20 |
| US20020072604A1 (en) | 2002-06-13 |
| TNSN01097A1 (fr) | 2005-11-10 |
| ECSP024404A (es) | 2003-02-06 |
| IS6617A (is) | 2002-11-14 |
| PE20020208A1 (es) | 2002-03-13 |
| JP2004501917A (ja) | 2004-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200210277B (en) | Melanocortin receptor ligands. | |
| CA2860951C (en) | Imidazopyrrolidinone compounds | |
| ES2285715T3 (es) | Secretagodos de la hormona del crecimiento. | |
| ES2377975T3 (es) | Composición medicinal que comprende un inhibidor de la HMG-CoA reductasa y un derivado de aminoalcohol como inmunodepresor | |
| CA2395593A1 (en) | Azaindoles | |
| US20090209573A1 (en) | Compounds and compositions as hedgehog pathway modulators | |
| US11052091B2 (en) | BRK inhibitory compound | |
| ES2586231T3 (es) | Inhibidores de glutaminil ciclasa | |
| CN111491934A (zh) | 作为激酶抑制剂的氨基-氟哌啶衍生物 | |
| JP2005508311A (ja) | ｏ−フェニレンジアミンのＮ−モノアシル化誘導体、その六員複素環式アナログ、及び薬剤としてのそれらの使用 | |
| JP2009502920A5 (pt) | ||
| JP2003500404A5 (pt) | ||
| KR20130029368A (ko) | Ｍｇｌｕｒ4 알로스테릭 강화제로서 피라졸로피리딘, 피라졸로피라진, 피라졸로피리미딘, 피라졸로티오펜 및 피라졸로티아졸 화합물, 조성물, 및 신경 기능이상을 치료하는 방법 | |
| ES2839248T3 (es) | Estimuladores y/o activadores de la guanilatociclasa soluble (sGC) en combinación con un inhibidor de la endopeptidasa neutra (inhibidor de NEP) y/o un antagonista de angiotensina AII y su uso | |
| JP7101688B2 (ja) | ｓＧＣ刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ | |
| CA2787323C (en) | Therapeutic or prophylactic agent for biliary tract diseases | |
| JP2019529521A (ja) | Ｓｇｃアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ | |
| JP2022501344A (ja) | 新規キナゾリンｅｇｆｒ阻害剤 | |
| EA002089B1 (ru) | Способ лечения резистентности к инсулину средствами, стимулирующими секрецию гормона роста | |
| JP2016132649A (ja) | 新規イミダゾピリジン誘導体およびその医薬用途 | |
| NZ230098A (en) | Compositions containing substituted 2,3-dihydroimidazo-(2,1-a) isoquinolines | |
| RU2012141061A (ru) | Агонист рецептора грелина для лечения кахексии | |
| AU2021327616A1 (en) | Pyrrolopyridine derivative and use thereof | |
| AU2012217903A1 (en) | Peripherially acting mu opioid antagonists | |
| JPH10502657A (ja) | ヘテロ環縮合モルヒノイド誘導体 |